Olga S. Vlasenko

Olga S. Vlasenko

Auto-generated profile, based on publicly available information

Olga S. Vlasenko

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2025 in Russian Journal of Anesthesiology and Reanimatology
Verified
Journal Article
Closed access
OVO.S. Vlasenko
O.S. Vlasenko
APA.N. Polyakov
A.N. Polyakov
SMS.O. Matveeva
S.O. Matveeva
NKN.E. Kudashkin
N.E. Kudashkin
OEO.A. Egenov
O.A. Egenov
ASA.V. Sytov
A.V. Sytov
Objective. To evaluate the effect of first-day infusion and pancreatic acinar structures on the incidence of postoperative pancreatic fistulas (POPF) and complications after pancreatoduodenectomy. Material and methods. A retrospective study included patients who underwent pancreatoduodenectomy in 2024. Results. There were 79 patients: group 1 (n=38) — infusion ≥4.5 ml/kg/h on day 1, group 2 (n=41) — infusion <4.5 ml/kg/h. The median of acinar structures was 65%. POPF were found in 23.6% (n=9) and 53.6% (n= 22) of patients, respectively (p=0.021). POPF type B prevailed (21.0% (n=8) and 51.2% (n=21) of patients, respectively, p=0.033). Clavien-Dindo grade III—V complications occurred in 26.3% (n=10) and 58.5% (n=24) of patients, respectively (p=0.022). Multifactorial analysis showed that daily infusion <4.5 ml/kg/h (OR=3.938; 95% CI 1.461—10.614; p=0.025) and acinar structures ≥65% (OR=12.889; 95% CI 4.285—38.772; p=0.001) were predictors of type B POPF. Acinar structures ≥65% were predictors of Clavien-Dindo grade ≥III complications (OR=11.487; 95% CI 3.853—34.243; p=0.003). Conclusion. Daily infusion <4.5 ml/kg/h (p=0.025) and acinar structures ≥65% (p=0.001) increase the incidence of type B POPF after pancreatoduodenectomy. Acinar structures ≥65% increase the incidence of Clavien-Dindo ≥ grade III complications (p=0.003).

26 June 2026 in Supportive Therapy in Oncology
Verified
Journal Article
Closed access
PDF file
ASAleksandr V. Sуtov
Aleksandr V. Sуtov
СВСытов Александр Викторович
Сытов Александр Викторович
AYAnna I. Yukhina
Anna I. Yukhina
ЮИЮхина А. И.
Юхина А. И.
OVOlga S. Vlasenko
Olga S. Vlasenko
КВКононец П. В.
Кононец П. В.
Aim. То compare the safety of use and the analgesic effect of postoperative anesthesia regimens using non-steroidal anti-inflammatory drug (NSAID) – Intrafen-GEN (ibuprofen) with a scheme of postoperative anesthesia based on narcotic analgesics in oncological patients after thoracoscopic and bone-plastic surgery. To evaluate the possibilities of using a postoperative anesthesia regimen using NSAIDs – Intrafen-GEN (ibuprofen) within the framework of the ERAS protocol (Enhanced Recovery After Surgery). Materials and methods. A single-center prospective comparative study conducted at the N.N. Trapeznikov Research Institute of Clinical Oncology in 2024–2025 included 98 patients who underwent minimally invasive thoracic and bone-plastic surgery. Results. Based on the area of surgical intervention, all patients (n=98) were divided first into 2 groups, and then into subgroups A and B, according to the schemes of postoperative anesthesia. The first group included 64 patients. It was divided into subgroups A (n = 34) and B (n = 30). The second group included 34 patients and was also divided into subgroups A and B with an equal number of patients in each of the subgroups (n = 17). Patients in subgroup A received a postoperative pain relief regimen using Intrafen-GEN (ibuprofen), and patients in subgroup B received a regimen using trimeperidine. The first intravenous dose of Intrafen-GEN (ibuprofen) – 800 mg was administered 30 minutes before the end of surgery or immediately upon admission to the intensive care unit, then every 8–12 hours for 3 days. In the case of persistent pain, non-opioid and opioid analgesics were added to the treatment until the pain completely disappeared. Patients in subgroup B received anesthesia with trimeperidine 20 mg intramuscularly every 8 hours for 3 postoperative days. The quality of anesthesia in the postoperative period was assessed using the visual analog scale. Conclusion. In our study, Intrafen-GEN (ibuprofen) was found to be a safe drug, as no complications or side effects were observed during its use. The pain management regimens based on Intrafen-GEN (ibuprofen) demonstrated the complete elimination of opioid analgesics from postoperative pain management in 24 (70.59 %) patients after thoracoscopic surgeries and in 10 (58.85 %) patients after bone-plastic surgeries. When using Intrafen-GEN (ibuprofen), there are no contraindications for the ERAS protocol and early activation of patients in the ICU.

14 April 2025 in Russian Journal of Anesthesiology and Reanimatology
Verified
Journal Article
Closed access
OVO.S. Vlasenko
O.S. Vlasenko
NPN.A. Pluzhnikova
N.A. Pluzhnikova
ASA.R. Shin
A.R. Shin
EIE.F. Ilyin
E.F. Ilyin
DPD.V. Podluzhny
D.V. Podluzhny
ASA.V. Sytov
A.V. Sytov
Objective. To evaluate the effect of intravenous infusion volume on the first day after gastropancreatoduodenal resection (GPDR) on postoperative outcomes in cancer patients. Material and methods. The study retrospectively included 70 patients who underwent GPDR for pancreatic and periampular cancer in 2023. Results. Patients were divided into two groups: group 1 (n=35) received intravenous infusion volume ≥6.500 ml on the first postoperative day, group 2 (n=35) received infusion volume 6.500 ml does no increase in the risk of mortality and postoperative complications. Further research is needed to clarify the relationship between various indicators.

1 July 2025 in Supportive Therapy in Oncology
Verified
Journal Article
Open access
PDF file
ASAlexander V. Sytov
Alexander V. Sytov
OVOlga S. Vlasenko
Olga S. Vlasenko
ENEkaterina N. Nikolaeva
Ekaterina N. Nikolaeva
PKPavel V. Kononets
Pavel V. Kononets
OAOmar B. Abu-Haidar
Omar B. Abu-Haidar
MIMaksat A. Ibraev
Maksat A. Ibraev
Aim. To study the effect of volume infusion on the first 24 hours after Lewis esophageal resection with gastric esophagoplasty (combined laparotomy and thoracotomy access on the right) on the immediate results and outcomes in cancer patients.Materials and methods. The study retrospectively included patients who underwent Lewis resections of the esophagus with gastric esophagoplasty (combined laparotomy and thoracotomy access on the right) for malignant neoplasms of esophagus, as well as cardioesophageal cancer at the N.N. Blokhin National Medical Research Center of Oncology in 2023.Results. Forty patients were included in the study. The patients were divided into 2 groups based on the median rate of daily infusion therapy: in patients of group 1 (n = 21) on the 1st day of surgery, the intravenous infusion rate was ≥4 ml/kg/day, in patients of group 2 (n = 19) – 4 ml/kg/day. The complication rate was 47.7 % (n = 10) in group 1 and 84.2 % (n = 16) – in group 2 (p = 0.021). The incidence of complications ≥III grade according to Clavien–Dindo classification did not differ in both groups (p = 1.000). The incidence of postoperative deep vein thrombosis was 4.8 % (n = 1) in group 1 and 31.6 % (n = 6) in group 2 (p = 0.039). Ninety-day postoperative mortality was not observed in any of the groups. The length of hospital stay for patients in group 1 was 17 (15–18) days, in group 2 –16 (14–20) days (p = 0.707).Conclusion. The results of the study revealed that the number of common complications and the frequency of postoperative deep vein thrombosis in patients of the group 2, who received a daily infusion volume of 4 ml/kg/day, was higher than in patients of the group 1. The data from this study should be taken into account when planning infusion therapy in patients with esophageal malignancies and cardioesophageal cancer during Lewis esophageal resections with gastric esophagoplasty (combined laparotomy and thoracotomy access on the right).